A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma

2023-510017-26-00 Protocol CT-P51 1.1 Human pharmacology (Phase I) - First administration to humans Authorised, recruiting

Start 2 Oct 2024 · Status Authorised, recruiting · 6 EU/EEA countries · 16 sites · Protocol CT-P51 1.1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruiting
Participants planned 180
Countries 6
Sites 16

Completely Resected Stage IIB, IIC, and III Melanoma

Key facts

Sponsor
Celltrion Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
2 Oct 2024 → ongoing
Decision date (initial)
2024-09-05
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Completely Resected Stage IIB, IIC, and III Melanoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Celltrion Inc.

Sponsor organisation
Celltrion Inc.
Address
23 Academy-Ro, Yeonsu-Gu Yeonsu-Gu
City
Incheon
Postcode
22014
Country
Korea, Republic of

Scientific contact point

Organisation
Celltrion Inc.
Contact name
Clinical Planning

Public contact point

Organisation
Celltrion Inc.
Contact name
Yelim Jang

Locations

6 EU/EEA countries · 16 investigational sites

By country

CountryMS statusPlanned subjectsSites
Croatia Not authorised 8 1
Italy Ended 6 2
Poland Ongoing, recruitment ended 11 1
Romania Ongoing, recruitment ended 21 3
Slovenia Ended 7 1
Spain Ongoing, recruitment ended 30 8
Rest of world
Moldova, Republic of, Brazil, South Africa, Ukraine, Georgia, North Macedonia, Albania, Turkey, Peru, Serbia
97

Investigational sites

Croatia

1 site · Not authorised
Specijalna Bolnica Medico
oncology, Agaticeva 8, 51000, Rijeka

Italy

2 sites · Ended
Azienda Ospedaliera Universitaria Senese
UOC Immonoterapia Oncologica, Strada Delle Scotte 14, 53100, Siena
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Oncology Department, Via Piero Maroncelli 40, 47014, Meldola

Poland

1 site · Ongoing, recruitment ended
Uniwersyteckie Centrum Kliniczne
Centrum Wsparcia Badan Klinicznych UCK Osrodek Badan Klinicznych Wczesnych Faz, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk

Romania

3 sites · Ongoing, recruitment ended
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca
Medical Oncology, Strada Republicii 34-36, 400015, Cluj-Napoca
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti
Medical Oncology, Soseaua Fundeni 252, 022328, Bucharest
Centrul De Oncologie SF Nectarie S.R.L.
Oncology, Strada Caracal Nr 109, 200542, Craiova

Slovenia

1 site · Ended
Institute Of Oncology Ljubljana
Department of Surgical Oncology, Zaloska Cesta 2, 1000, Ljubljana

Spain

8 sites · Ongoing, recruitment ended
Hospital Universitario De Torrejon
Oncology, Calle De Mateo Inurria 1, 28850, Torrejon De Ardoz
Hospital Universitari Dexeus Grupo Quironsalud
Medical Oncology, Calle De Sabino Arana 5-19, 08028, Barcelona
Hospital San Pedro De Alcantara
Medical Oncology, Avenida De Pablo Naranjo Porras S/n, 10002, Caceres
Hospital Universitario Marques De Valdecilla
Medical Oncology, Avenida Valdecilla Sn, 39008, Santander
Hospital Universitario 12 De Octubre
Medical Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitario Virgen De La Victoria
Medical Oncology, Calle Del Arroyo Teatinos Sn, 29010, Malaga
Institut Catala D'oncologia
Oncology, Carretera Canyet S/n, 08916, Badalona
Parc Tauli Hospital Universitari
Oncology, Parc Del Tauli 1 Edifici Santa Fe Ala Izquierda Planta 2ª, 08208, Sabadell

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2024-12-13
Poland 2024-11-06 2025-04-01 2025-11-17
Romania 2024-10-02 2024-10-24 2025-12-10
Slovenia 2024-10-23 2025-03-24 2025-12-09
Spain 2024-10-14 2024-11-06 2025-12-10

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-17 Spain Acceptable
2024-08-23
2024-08-23
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-30 Spain Acceptable
2024-11-19
2024-11-21
3 SUBSTANTIAL MODIFICATION SM-2 2025-02-19 Spain Acceptable
2025-04-21
2025-04-22
4 SUBSTANTIAL MODIFICATION SM-3 2025-06-24 Spain Acceptable
2025-08-19
2025-08-21
5 SUBSTANTIAL MODIFICATION SM-6 2026-02-11 Spain Acceptable
2026-04-07
2026-04-13